Sensus Healthcare CEO Shares A Look Into Skin Cancer Treatment


Sensus Healthcare Inc (NASDAQ: SRTS) (NASDAQ: SRTSU) is micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO Joseph C. Sardano, who shared some insight into the company and its IPO.

What Makes SRT Special

Unlike all other skin cancer treatment products in the market, Sensus’ system (SRT) can be used by dermatologists in their offices, without the oversight of radiation oncologists and medical physicists, Sardano began. However, this does not mean that radiation oncologists are not using this machine as well.

In fact, he continued, radiation oncologists tend to agree that “superficial radiation therapy is the best way to treat skin cancer,” a condition that affects about 6 million people per year in the United States, at an annual cost of more than $8 billion.

“Other modes of radiation are not the best way to treat skin cancer because of the radiation dose and because of how sensitive the skin is. Our system only penetrates 5 millimeters below the surface of the skin, which makes it perfect for basal cell and squamous cell [carcinoma],” the two most common kinds of skin cancer.

Click here to read the full article.

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries